Journal of Neural Transmission

, Volume 111, Issue 12, pp 1583–1592

Reduced GSK-3β mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients

  • N. Kozlovsky
  • C. Shanon-Weickert
  • E. Tomaskovic-Crook
  • J. E. Kleinman
  • R. H. Belmaker
  • G. Agam
Article

DOI: 10.1007/s00702-004-0166-3

Cite this article as:
Kozlovsky, N., Shanon-Weickert, C., Tomaskovic-Crook, E. et al. J Neural Transm (2004) 111: 1583. doi:10.1007/s00702-004-0166-3

Summary.

Glycogen Synthase Kinase (GSK)-3 is a ubiquitous serine/threonine protein kinase highly abundant in brain which plays a key role in neural development and neuron survival. We have previously reported that GSK-3β protein levels and GSK-3 activity are reduced by over 40% in postmortem prefrontal cortex of schizophrenic patients compared to patients with bipolar illness, unipolar depression and to normal controls, and Emamian et al. have recently presented convergent evidence for impaired AKT1-GSK-3β signaling in schizophrenia. Using specimens of dorsolateral prefrontal cortex tissue obtained from The Stanley Medical Research Institute’s Brain Collection, from the same subjects used previously, we now show that GSK-3β, but not GSK-3α, mRNA levels are 36% lower in the patients with schizophrenia compared to all other comparison groups. The present study lends further support to the finding of low GSK-3β levels in schizophrenia and extends this observation by suggesting that the decrease in GSK-3β may be due to reduced protein synthesis possibly due to altered transcriptional drive of the GSK-3β gene.

Keywords: Glycogen Synthase Kinase (GSK)-3, mRNA, schizophrenia 

Copyright information

© Springer-Verlag/Wien 2004

Authors and Affiliations

  • N. Kozlovsky
    • 1
  • C. Shanon-Weickert
    • 3
  • E. Tomaskovic-Crook
    • 3
  • J. E. Kleinman
    • 3
  • R. H. Belmaker
    • 1
  • G. Agam
    • 1
    • 2
  1. 1.Stanley Research Center, Ben Gurion University of the Negev and Mental Health CenterBeershevaIsrael
  2. 2.Department of Clinical Biochemistry, Faculty of Health SciencesBen Gurion University of the Negev and Mental Health CenterBeershevaIsrael
  3. 3.Clinical Brain Disorders Branch, IRP/NIMH/NIHBethesdaUSA

Personalised recommendations